Topical Dosage for Treatment of ChemotherapyInduced Peripheral Neuropathy
DOI:
https://doi.org/10.61841/85v4jb75Keywords:
Peripheral neuropathy, chemotherapy, CIPN, pharmacological agents, allodynia, hyperalgesia, topicalAbstract
Peripheral neuropathy caused by chemotherapy is a general therapeutic limiting factor that greatly affects patients ' daily lives, mostly due to lack of appropriate palliative options. CIPN is a severe, often chronic condition with pain and reduced function. In addition, CIPN is its most common dose-limiting side effect, which is decreasing and could affect treatment outcomes. Interestingly, the incidence of paclitaxel (taxane) induced peripheral neuropathy is very high ranging from 53-83% with severity in 2-33% patients. The clinical symptoms of CIPN affect sensory, motor and sometimes autonomic functions. A sensory disturbance includes allodynia, hyperalgesia and spontaneous sensations such as tingling, burning, electric, stabbing, numbness, and prickling. Hence, considering the drawbacks of existing treatments, this study provides a topical gel comprising of pharmacological agents with multiple mechanisms of action and regeneration of damaged nerve fibres. The formulated gel successfully qualified the tests for semi-solid dosage form such as color, appearance, and homogeneity, measurement of pH, viscosity, spreadability, drug content and stability.
Downloads
References
[1] D. Balayssac et al., “Chemotherapy-induced peripheral neuropathies: From clinical relevance to preclinical
evidence,” Expert Opinion on Drug Safety, vol. 10, no. 3. Informa Healthcare, pp. 407–417, 2011.
[2] S. Quasthoff and H. P. Hartung, “Chemotherapy-induced peripheral neuropathy,” Journal of Neurology,
vol. 249, no. 1. D. Steinkopff-Verlag, pp. 9–17, 2002.
[3] J. Piccolo and J. M. Kolesar, “Prevention and treatment of chemotherapy-induced peripheral neuropathy,”
Am. J. Heal. Pharm., 2014.
[4] A. J. Windebank and W. Grisold, “Chemotherapy-induced neuropathy,” Journal of the Peripheral Nervous
System, vol. 13, no. 1. pp. 27–46, Mar-2008.
[5] S. Hou, B. Huh, H. K. Kim, K. H. Kim, and S. Abdi, “Treatment of chemotherapy-induced peripheral
neuropathy: Systematic review and recommendations,” Pain Physician. 2018.
[6] D. R. Pachman, D. L. Barton, J. C. Watson, and C. L. Loprinzi, “Chemotherapy-induced peripheral
neuropathy: Prevention and treatment,” Clin. Pharmacol. Ther., 2011.
[7] D. L. Hershman et al., “Prevention and management of chemotherapy-induced peripheral neuropathy in
survivors of adult cancers: American society of clinical oncology clinical practice guideline,” Journal of
Clinical Oncology. 2014.
[8] H. J. Park, “Chemotherapy induced peripheral neuropathic pain,” Korean Journal of Anesthesiology. 2014
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
